PATENT CLAIM ANALYSIS

Application Number: 16161170
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-09
Patent Classification: ["514", "001300"]

Abstract:
Disclosed are prodrugs of anthracyclines (such as doxorubicin) and derivatives thereof that are selectively cleaved and activated by fibroblast activating protein (FAP). The prodrugs are useful for targeted delivery of “warhead” anthracycline or anthracycline derivative to FAP-expressing tissues, including cancer (e.g., solid tumors). Also provided are pharmaceutical compounds comprising the prodrugs, as well as methods of using the prodrugs to treat a disorder characterized by FAP upregulation, e.g., cancer, undesirable fibrosis, and undesirable inflammation.

Claim (Index 63):
The pharmaceutical preparation of  claim 62 , wherein X is O, and is aryl(C 1 -C 6 )acyl.

Metadata:
- Claim Count in Document: 98.0
- Percentile: 97.0
- Lexical Diversity: 1.53333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15655317', '15318627', '15318607', '14241666', '15952648']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8208449730747334
- 35 USC 102 Novelty (BERT): 0.5975971243891757
- Combined Prediction Score: 0.7985201882061775
- Mean Citation Score: 489.92086
- Max Citation Score: 640.4959
- Similarity Product: 402.1596667606115

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test